Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACS early lipid-target attainment trial with rosuvastatin-based strategies
ChiCTR-IPR-15006636Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rosuvastatin and ezetimibe in acute coronary syndrome (ACS) and dyslipidemia (3 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: alanine aminotransferase, aspartate aminotransferase and 8 more. Started Jul 2015; status: recruiting.
02
Drugs
rosuvastatinezetimibe
03
Conditions
acute coronary syndrome (ACS)dyslipidemia
Beyond the preview
Go deeper on ChiCTR-IPR-15006636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006636.